CMPS COMPASS Pathways plc
Stock Price & Overview

$13.130.48 (+3.79%)11:30 AM 06/24/26
NASDAQ | $USD | Realtime

CMPS Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

CMPS Analysis

See All Analysis »

CMPS News

See All News

CMPS Latest Headlines

CMPS Seasonality

Displays mean and median monthly returns for CMPS in order to identify seasonal patterns.
YearJanFebMarAprMayJunJulAugSepOctNovDec

CMPS Ratings Summary

People Also Follow

Similar to CMPS

ETFs Holding CMPS

CMPS Company Profile

COMPASS Pathways plc logo
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Sector
Health Care
Industry
Biotechnology
Employees
156
Founded
2020
Address
  • 33 Broadwick Street
  • London, W1F 0DQ
  • United Kingdom
Phone Number
44 716 6766461
Website
compasspathways.com
Hide

CMPS Revenue

More On Revenue

CMPS Earnings Per Share

More On Earnings

Earnings Estimates

Earnings Revisions

Valuation

Profitability

Momentum

Capital Structure

CMPS Ownership

CMPS Peers

Risk

Technicals

CMPS Transcripts

CMPS Investor Presentations

CMPS SEC Filings

See All SEC Filings

CMPS Press Releases

See All Press Releases

CMPS Income Statement

CMPS Balance Sheet

CMPS Cash Flow Statement

CMPS Long Term Solvency

COMPASS Pathways plc (CMPS) Frequently Asked Questions